Ann Oncol: Efficacy of atezolizumab combined with albumin-bound paclitaxel in the first-line treatment of unresectable, locally advanced or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis

Triple negative breast cancer (TNBC), lack of estrogen or progesterone receptors on the cell surface, and no overexpression or amplification of human epidermal growth factor receptor 2 (HER2), is usually associated with a poor prognosis
.

The global, randomized, double-blind phase III clinical study IMpassion130 mainly evaluates atezolizumab combined with albumin-bound paclitaxel (A + nP) vs.

Triple negative breast cancer (TNBC), lack of estrogen or progesterone receptors on the cell surface, and no overexpression or amplification of human epidermal growth factor receptor 2 (HER2), is usually associated with a poor prognosis

A total of 902 patients were enrolled, and the two groups of ITT included 451 patients each; and the PD-L1 positive population included 369 patients, of which atezolizumab combined with albumin-bound paclitaxel (A + nP) was 185, comfort 184 cases were combined with albumin-bound paclitaxel (P+nP)
.

The safety assessment population includes 460 patients in the (A + nP) group and 430 patients in the (P+nP) group

A total of 902 patients were enrolled, and the two groups of ITT included 451 patients each; and the PD-L1 positive population included 369 patients, of which atezolizumab combined with albumin-bound paclitaxel (A + nP) was 185, comfort 184 cases were combined with albumin-bound paclitaxel (P+nP)

The median follow-up time was 18.

OS in ITT and PDL1 positive people

OS in ITT and PDL1 positive people

A stratified analysis of the ITT population and the PD-L1 positive population revealed that most subgroups of the ITT population did not benefit, while most subgroups of the PDL-1 positive population could benefit from the (A + nP) group
.

In the ITT population, the 36-month OS rates in the (A + nP) group and (P+nP) group were 28.

A stratified analysis of the ITT population and the PD-L1 positive population revealed that most subgroups of the ITT population did not benefit, while most subgroups of the PDL-1 positive population could benefit from the (A + nP) group

PD-L1 positive subgroup analysis OS

PD-L1 positive subgroup analysis OS

Adverse events (AEs) of any grade in the (A + nP) group and (P+nP) group were 457 (99%) and 421 (98%), respectively.
The common ones were hair loss, fatigue, and nausea
.

The proportions of treatment interruption in the two groups were 19% and 8%, respectively, mostly due to neuropathic pain

Adverse events (AEs) of any grade in the (A + nP) group and (P+nP) group were 457 (99%) and 421 (98%), respectively.

Adverse events

Adverse events

In summary, in the ITT population, atezolizumab combined with albumin-bound paclitaxel does not improve the patient's OS
.

However, in the PD-L1 positive population, atezolizumab combined with albumin-bound paclitaxel significantly improved the patient's OS

In summary, in the ITT population, atezolizumab combined with albumin-bound paclitaxel does not improve the patient's OS

Original source:

LA Emens, S.
Adams, CH Barrios, et al.
First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis.
Annals of Oncology, 2021, https:/ /doi.
org/10.
1016/j.
annonc.
2021.
05.
355.

LA Emens, S.
Adams, CH Barrios, et al.
First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis.
Annals of Oncology, 2021, https:/ /doi.
org/10.
1016/j.
annonc.
2021.
05.
355.
Leave a message here